This morning, our partner @MelintaTx announced the commercial availability of rezafungin in the U.S. Read here for more information on other program updates: https://t.co/2C1lDskL9G pic.twitter.com/vZGCyq7Chm

— Cidara Therapeutics (@CidaraThera) July 31, 2023

Today marks a significant milestone as we received authorization to initiate a Phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy in the United Kingdom. https://t.co/2ydSs9Xe4r #BiotechNews $TRDA pic.twitter.com/aUu6bt21lA

— Entrada Therapeutics (@entradatx) August 1, 2023

Today we announce positive data from our Phase Ib/IIa study of NT-0796 in #ParkinsonsDisease. For the first time a brain penetrant #NLRP3 #inflammasome inhibitor has demonstrated a reduction in markers of #neuroinflammation in a clinical setting. For more: https://t.co/fqcuuFY9Fk pic.twitter.com/3CqtZ0C6mI

— NodThera (@NodThera) July 11, 2023